RecruitingPhase 2NCT05345002

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Studying Glial tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stephen Bagley, MD, MSCE
Principal Investigator
Stephen Bagley, MD MSCE
University of Pennsylvania
Intervention
Retifanlimab(drug)
Enrollment
55 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2028

Study locations (1)

Collaborators

Incyte Corporation · Abramson Cancer Center at Penn Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05345002 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor →

← Back to all trials